Vireo Growth VREOF
OTC VREOF
$10.97 -0.01 (-0.09%)
At close: Aug 19, 2026 · 3:35 PM UTC

Vireo Growth (VREOF) Income towards Parent Company (2020 - 2026)

Vireo Growth (VREOF) posted Income towards Parent Company of -$22.5 million for Q1 2026, up 33.39% sequentially from -$33.8 million in Q4 2025, and down 562.98% YoY from $4.9 million in Q1 2025.

Vireo Growth (VREOF) Income towards Parent Company (2020 - 2026) Analysis & Trends

Vireo Growth has reported Income towards Parent Company for 7 years, with the latest figure at -$22.5 million in Q1 2026.

  • Quarterly Income towards Parent Company fell 562.98% year-over-year to -$22.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.8 million (down 384.51% YoY) and the FY2025 annual result came in at -$81.5 million, down 598.32% from the prior year.
  • Income towards Parent Company advanced to -$22.5 million in Q1 2026 per VREOF's latest filing, from -$33.8 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $4.9 million in Q1 2025 and troughed at -$33.8 million in Q4 2025.
  • A 5-year average of -$5.3 million and a median of -$5.7 million in 2023 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2024 and 2025: Income towards Parent Company surged 176.72% in 2024, then tumbled 903.06% in 2025.
  • Over 5 years, Income towards Parent Company stood at -$9.3 million in 2022, then jumped by 138.44% to $3.6 million in 2023, then rose by 17.77% to $4.2 million in 2024, then sank by 903.06% to -$33.8 million in 2025, then soared by 33.39% to -$22.5 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$22.5 million, -$33.8 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 43.76 Bn 42.80 Bn -
2 Teva Pharmaceutical Industries 43.05 Bn 39.39 Bn 2.15 Bn
3 Zoetis 31.51 Bn 29.84 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.70 Bn 22.90 Bn 5.10 Bn
5 United Therapeutics 22.27 Bn 19.61 Bn 683.80 Mn
6 Viatris 18.83 Bn 17.95 Bn 1.46 Bn
7 Neurocrine Biosciences 15.65 Bn 15.26 Bn 935.80 Mn
8 Elanco Animal Health 12.06 Bn 11.53 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.12 Bn 9.95 Bn -
10 Vireo Growth 493.25 Mn 350.95 Mn 95.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -22.50 Mn
Dec 31, 2025 -33.78 Mn
Sep 30, 2025 2.76 Mn
Jun 30, 2025 3.67 Mn
Mar 31, 2025 4.86 Mn
Dec 31, 2024 4.21 Mn
Sep 30, 2024 4.40 Mn
Jun 30, 2024 4.06 Mn
Mar 31, 2024 3.70 Mn
Dec 31, 2023 3.57 Mn
Sep 30, 2023 -5.73 Mn
Jun 30, 2023 -7.39 Mn
Mar 31, 2023 -8.47 Mn
Dec 31, 2022 -9.29 Mn
Sep 30, 2022 -9.57 Mn
Jun 30, 2022 -6.10 Mn
Mar 31, 2022 -17.68 Mn
Dec 31, 2021 -14.09 Mn
Sep 30, 2021 -6.84 Mn
Jun 30, 2021 -6.99 Mn